Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
IBSA Pharma
Antibes, Provence-Alpes-Côte d'Azur, Franceibsa-pharma.fr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
One approved small molecule drug (diclofenac epolamine) targeting COX-1 and COX-2 for acute pain, plus clinical-stage programs in dermatology, diabetic wound repair, psoriasis, and other areas[5]. Continually launches new products such as skin repair and filler devices[4]. Clinical trials include randomized and controlled studies for medical devices and dermatological treatments[5].
- Therapeutic areas
- ImmunologyEndocrinologyRheumatologyDermatologyNeurology
- Modalities
- Small moleculeMedical deviceCosmeticFood supplement
- Industry
- Biotech
02
Partnerships
IBSA Institut Biochimique (historical distributor/acquirer)
Beyond the preview
Go deeper on IBSA Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBSA Pharma.